Association of Thiamine Use with Outcomes in Patients with Sepsis and Alcohol Use Disorder: An Analysis of the MIMIC-III Database.

INTRODUCTION: The association between thiamine use and clinical outcomes among patients with sepsis and alcohol use disorder (AUD) is unclear.
METHODS: In this retrospective cohort study of patients from Medical Information Mart for Intensive Care III (MIMIC-III, version 1.4), we evaluated the association of thiamine use with clinical outcomes in patients with AUD and sepsis. The primary outcome was 28-day survival, and secondary outcomes included ICU, in-hospital, and 90-day mortality, ICU and hospital length of stay, duration of vasopressor use, need and duration of continuous renal replacement therapy (CRRT), and dynamic changes for variables up to day 7 after ICU admission.
RESULTS: A total of 944 patients with sepsis and AUD were included in this cohort [median age, 53.1 years; women, 26.0% (245 of 944)]. Among all patients, 24.6% (233 of 944) received thiamine with a dose of 200 mg (IQR 100-345 mg). The 28-day mortality was 11.2% (26 of 233) in the thiamine use group compared with 18.6% (132 of 711) in the no thiamine use group (P = 0.009). After adjustment for a series of confounders, the mixed-effects Cox proportional hazards models showed that administration of thiamine was associated with a lower risk of 28-day mortality compared with no administration of thiamine.
CONCLUSIONS: In critically ill patients with alcohol use disorder admitted for sepsis, treatment with thiamine may be associated with a decreased risk of death. However, the present results should be interpreted with caution due to the limitations of retrospective design. Additional larger, multicenter randomized controlled trials are needed to confirm our findings.

Key Summary Points

Introduction

Among patients with alcohol use disorder (AUD), sepsis is common, leading to adverse outcomes, including death [1, 2]. In addition, critically ill patients with sepsis or AUD are frequently thiamine deficient due to malnutrition or malabsorption [3-5]. Thiamine supplementation is not routinely used for critically ill patients. However, previous studies have suggested that treatment with thiamine may result in improved outcomes in critically ill individuals, especially in patients with sepsis and AUD [6, 7]. Nonetheless, a recent observational cohort study of 68,571 patients with septic shock demonstrated that thiamine administration did not improve the 28-day survival compared with no thiamine administration [8]. On the other hand, among patients with sepsis and AUD, Holmberg et al. [9], in a small cohort (N = 53), reported a decreased mortality rate among those who received thiamine.

In the current study, we aimed to investigate the association between thiamine administration and the 28-day mortality among patients with sepsis and AUD in a large cohort of patients. We hypothesized that administration of thiamine leads to improved 28-day survival compared with no thiamine use.

Methods

Ethics Approval

The establishment of the Medical Information Mart for Intensive Care III (MIMIC-III, version 1.4) was approved by the Massachusetts Institute of Technology (Cambridge, MA) and Beth Israel Deaconess Medical Center (Boston, MA), and consent was obtained for the original data collection. Therefore, the ethical approval statement and the need for informed consent were waived for this manuscript.

Study Design

This retrospective cohort study was based on the MIMIC-III. The MIMIC-III is a large, single-center, freely accessible critical care database, which comprises over 60,000 individuals admitted to ICU at the Beth Israel Deaconess Medical Center from 2001 to 2012 [10]. We accessed the MIMIC-III after completion of the Protecting Human Research Participants exam (No. 30380922). In the MIMIC-III database for patient privacy, all participants are deidentified. In addition, we followed the Reporting of Studies Conducted Using Observational Routinely Collected Health Data reporting (RECORD) guidelines [11].

Patients

We included adult patients (at least 18 years old) with AUD defined by the International Classification of Diseases, 9th edition [ICD-9] codes (Supplementary Table S1), and admitted to ICU for sepsis identified by the Sepsis 3.0 criteria [12]. Patients with documented or suspected infection with Sequential Organ Failure Assessment [SOFA] [13] score of at least 2 before or within 24 h of ICU admission met the sepsis definition (Supplementary Fig. S1). Among those with multiple ICU admissions, we analyzed only the first ICU admission. Additionally, we excluded patients undergoing cardiothoracic surgery and had missing information regarding the primary outcome.

Clinical and Laboratory Data

We collected baseline demographic information, comorbidities, admission type, primary infection site, the vital sign and laboratory values on day 1, illness severity scores (i.e., Glasgow Coma Scale [GCS] [14], Model for End-Stage Liver Disease [MELD] [15], SOFA, Oxford Acute Severity of Illness Score [OASIS] [16], Logistic Organ Dysfunction score [LODS] [17]) on day 1, and the need for mechanical ventilation or vasopressors on the first day of ICU admission. In addition, the mean values of vital signs in the first 24 h in the ICU were collected, including heart rate, respiratory rate, systolic blood pressure, diastolic blood pressure, and body temperature. The maximum laboratory values in the first 24 h of the ICU admission were abstracted, including lactate, white blood cell count, prothrombin time, activated partial thromboplastin time, international normalized ratio, creatine kinase, creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine, blood urea nitrogen, serum sodium, serum potassium, serum chloride, and serum magnesium. The minimum values of hemoglobin, platelet, and albumin during the first 24 h of the ICU admission were also collected. We selected the maximum severity of illness scores in the first 24 h of the ICU admission (MELD, SOFA, OASIS, LODS), except GCS, for which we chose its minimum values. In addition, heart rate, respiratory rate, systolic blood pressure, lactate, white blood cell count, alanine aminotransferase, aspartate aminotransferase, serum creatinine, blood urea nitrogen, serum magnesium, GCS and MELD values were collected from day 1 to day 7 after ICU admission. The cumulative dose of thiamine (defined as the total amount of drug received during the ICU stay) and the daily dose of thiamine (defined as the total amount of drug received in daily) were also collected.

Outcomes

The primary outcome was 28-day mortality. Secondary outcomes included ICU, hospital, and 90-day mortality rates, ICU and hospital length of stay, duration of vasopressor and continuous renal replacement therapy (CRRT) use, and dynamic changes of heart rate, respiratory rate, systolic blood pressure, lactate, white blood cell count, alanine aminotransferase, aspartate aminotransferase, serum creatinine, blood urea nitrogen, serum magnesium, GCS and MELD up to day 7 following ICU admission.

Statistical Analysis

We determined the normality of the distribution for continuous variables by the Kolmogorov–Smirnov test. We reported the normally distributed variables as the means ± standard deviation (SD), the skewed distributed variables as the median and interquartile range (IQR). The categorical variables were expressed as numbers and percentages. Among the groups, we compared continuous variables by Student t test or Mann–Whitney U test, as appropriate. Categorical variables were compared by Pearson’s chi-squared test or Fisher’s exact test, as appropriate. The sample size was calculated to maintain event (28-day mortality) per variable ratio of 10:1 in the regression models.

A priori-defined variables were selected for the multivariate Cox regression analysis because of their plausible association with 28-day mortality. Additionally, considering potential confounders that were not fully balanced between two groups (P < 0.05), we conducted Cox proportional hazard model to adjust for these confounders including primary infection site, heart rate, blood pressure, international normalized ratio, total bilirubin, serum creatinine, blood urea nitrogen, serum potassium, GCS, MELD, and OASIS. To avoid overadjusting for potential confounders (such as MELD score which contains total bilirubin, international normalized ratio, and serum creatinine), we used six models with a gradual degree of adjustment. Model 1 was adjusted for age, gender, admission type, and primary infection site. Model 2 was adjusted for the confounders included in model 1 plus vital signs (heart rate and blood pressure). Model 3 was adjusted for the confounders included in model 2 plus laboratory tests (international normalized ratio, total bilirubin, serum creatinine, blood urea nitrogen, and serum potassium). Model 4 was adjusted for the confounders included in model 3 plus GCS. Model 5 was adjusted for the confounders included in model 2 plus GCS and MELD. Model 6 was adjusted for the confounders included in model 2 plus OASIS. The results were presented as the hazard ratio (HR) and associated 95% confidence interval (CI).

Kaplan–Meier survival curves using the log-rank test were drawn to assess mortality differences between the groups. In addition, we compared trends for heart rate, respiratory rate, systolic blood pressure, lactate, white blood cell count, alanine aminotransferase, aspartate aminotransferase, serum creatinine, blood urea nitrogen, serum magnesium, GCS, and MELD from day 1 to day 7. Generalized linear mixed models were used to estimate the conditional associations of thiamine treatment. We used restricted cubic spline fitted for Cox proportional hazards models relative to the median doses of thiamine therapy. Kernel density plots were used to demonstrate the distribution of quantities of thiamine used.

Subgroup analyses for the primary outcome were performed for (1) patients < 50 vs. ≥ 50 years old, (2) patients with serum lactate of < 2 vs. ≥ 2, (3) patients without need for mechanical ventilation vs. those on mechanical ventilator on the day 1, (4) patients without the need for vasopressors vs. those on vasopressor on day 1, (5) patients with day 1 SOFA score of < 5 vs. ≥ 5, and (6) patients with day 1 OASIS < 34 vs. ≥ 34. We did not impute the missing data as information for the primary outcome was available, and for the secondary outcomes was missing in at most 5% of patients.

Statistical analysis was performed using the statistical package IBM SPSS statistics software (SPSS) (version 24.0, Chicago, IL, USA), and figures were constructed using Origin (version 9.6. Northampton, Massachusetts, USA), R software (version 3.6.0). P values less than 0.05 represented statistical significance in the two-sided hypothesis.

Results

Baseline Characteristics

A total of 61,532 individuals from MIMIC-III were screened, and 1296 patients with AUD admitted for sepsis were included in the study. A total of 352 patients were excluded from the analysis (283 recurrent admissions, 62 patients with cardiothoracic surgery, and seven patients with missing data for the primary outcome). Thus, 944 patients (233 and 711 with and without thiamine supplementation, respectively) entered the final analyses (Fig. 1). The patient demographics and baseline characteristics were similar between the groups (the median (IQR) age was 53.1 [44.5–62.2], and 699 patients [74.0%] were male). Approximately 96% of the participants were admitted from the emergency department. There were no significant between-group differences in comorbidities, and the most common comorbidities were liver diseases (31.8%), followed by diabetes mellitus (17.3%) and congestive heart failure (10.5%). The underlying source of infection differed significantly between the two groups, with the bloodstream being the most common site of infection in the thiamine use group (44.1%), followed by lung (30.1%) and urine (21.4%), while with the lung being the most common site of infection in the no thiamine administration group (48.1%), followed by bloodstream (33.9%) and urine (15.9%). The demographic and clinical characteristics of the patients are summarized in Table 1.

Fig. 1

Detailed process of data extraction. MIMIC-III Medical Information Mart for Intensive Care III, ICU intensive care unit

Table 1

Baseline characteristics of included patients

Characteristics	All, n = 944	No thiamine, n = 711	Thiamine, n = 233	P value
Age, year	53.1 (44.5–62.2)	53.0 (44.1–62.7)	53.3 (44.6–61.2)	0.920
Sex, n (%)				0.346
Female	245 (26.0)	190 (26.7)	55 (23.6)
Male	699 (74.0)	521 (73.3)	178 (76.4)
BMI, kg/m2	27.1 (24.4–31.9)	27.6 (24.6–32.3)	26.1 (23.5–30.7)	0.068
Ethnicity, n (%)
White	674 (71.4)	506 (71.2)	168 (72.1)	0.784
Hispanic	27 (2.9)	21 (3.0)	6 (2.6)	0.764
Black	73 (7.7)	59 (8.3)	14 (6.0)	0.256
Other/unknown	170 (18.0)	125 (17.6)	45 (19.3)	0.550
Comorbidities, n (%)
Liver disease	300 (31.8)	234 (32.9)	66 (28.3)	0.192
Diabetes	163 (17.3)	125 (17.6)	38 (16.3)	0.656
Congestive heart failure	99 (10.5)	80 (11.3)	19 (8.2)	0.181
Renal failure	70 (7.4)	56 (7.9)	14 (6.0)	0.345
Hypertension	50 (5.3)	40 (5.6)	10 (4.3)	0.430
Solid tumor	36 (3.8)	32 (4.5)	4 (1.7)	0.054
Rheumatoid arthritis	13 (1.4)	9 (1.3)	4 (1.7)	0.535
Metastatic cancer	13 (1.4)	12 (1.7)	1 (0.4)	0.153
Admission type				0.205
Emergency	903 (95.7)	679 (95.5)	224 (96.1)
Elective	21 (2.2)	14 (2.0)	7 (3.0)
Urgent	20 (2.1)	18 (2.5)	2 (0.9)
Primary infection site				< 0.001
Bloodstream	392 (41.5)	313 (44.0)	79 (33.9)
Pneumonia	326 (34.5)	214 (30.1)	112 (48.1)
Renal/urinary tract	189 (20.0)	152 (21.4)	37 (15.9)
Others	37 (3.9)	32 (4.5)	5 (2.1)

BMI body mass index

Compared with those who did not receive thiamine, patients who received thiamine had a higher heart rate, systolic and diastolic blood pressures, shorter activated partial thromboplastin time, lower international normalized ratio, total bilirubin, serum creatinine, and blood urea nitrogen (Table 2). Patients who received thiamine had similar severity of illness scores (excluding GCS, MELD, and OASIS) and therapeutic options (included the percentage of mechanical ventilation, vasopressor, and CRRT) on day 1, compared with patients who did not receive thiamine (Table 3).

Table 2

Vital signs and laboratory findings of included patients

Characteristics	All, n = 944	No thiamine, n = 711	Thiamine, n = 233	P value
Vital sign
Heart rate, bpm	92 (81–104)	91 (80–102)	95 (83–107)	0.004
Respiratory rate	19 (17–22)	19 (17–22)	19 (17–23)	0.492
Systolic blood pressure, mmHg	116 (106–130)	115 (105–129)	121 (109–133)	0.001
Diastolic blood pressure, mmHg	63 (57–71)	63 (57–70)	67 (60–75)	< 0.001
Body temperature, °C	37.0 (36.5–37.5)	36.9 (36.5–37.5)	37.0 (36.6–37.6)	0.053
Laboratory tests
Lactate, mmol/L	2.7 (1.8–4.5)	2.8 (1.8–4.7)	2.4 (1.7–3.9)	0.170
White blood cell count, × 103/μL	12.3 (8.3–17.8)	12.5 (8.4–17.9)	11.9 (8.1–17.6)	0.212
Hemoglobin, g/dL	10.2 (8.8–11.9)	10.1 (8.6–11.9)	10.3 (9.1–12.0)	0.175
Platelet, × 103/μL	139 (82–211)	138 (80–213)	143 (89–202)	0.934
Prothrombin time, s	15.4 (13.4–19.1)	15.5 (13.5–19.1)	15.0 (13.1–18.5)	0.079
Activated partial thromboplastin time, s	32.9 (27.8–44.9)	33.6 (28.1–46.6)	31.5 (26.9–38.8)	0.012
International normalized ratio	1.4 (1.2–1.8)	1.4 (1.2–1.9)	1.3 (1.1–1.7)	0.005
Creatine kinase, U/L	312 (117–1405)	319 (107–1351)	301 (137–1866)	0.503
Creatine kinase–MB, U/L	8 (4–20)	8 (4–20)	9 (5–20)	0.301
Lactate dehydrogenase, U/L	304 (218–495)	298 (212–491)	315 (227–517)	0.223
Alanine aminotransferase, U/L	45 (24–112)	47 (24–117)	35 (23–101)	0.111
Aspartate aminotransferase, U/L	82 (41–232)	81 (41–235)	87 (38–201)	0.704
Total bilirubin, mmol/L	1.5 (0.6–4.4)	1.6 (0.7–4.6)	1.3 (0.6–3.4)	0.043
Serum creatinine, mg/dL	1.1 (0.8–1.8)	1.1 (0.8–1.8)	1.0 (0.7–1.8)	0.017
Blood urea nitrogen, mg/dL	20 (13–35)	21 (13–37)	17 (11–29)	0.001
Albumin, g/dL	2.9 (2.5–3.4)	2.9 (2.5–3.4)	3.0 (2.5–3.5)	0.499
Serum sodium, mmol/L	140 (137–143)	141 (137–144)	140 (137–143)	0.633
Serum potassium, mmol/L	4.3 (3.9–4.9)	4.4 (4.0–5.0)	4.2 (3.8–4.8)	0.016
Serum chloride, mmol/L	107 (103–111)	107 (103–111)	108 (103–111)	0.485
Serum magnesium, mg/dL	2.1 (1.9–2.4)	2.1 (1.9–2.4)	2.1 (1.9–2.4)	0.595

For the vital sign data, the mean value in the first 24 h in the ICU was selected for the following variables: heart rate, respiratory rate, systolic blood pressure, diastolic blood pressure, and body temperature. For laboratory data, the maximum value in the first 24 h in the ICU was selected for the following variables: lactate, white blood cell, prothrombin time, activated partial thromboplastin time, international normalized ratio, creatine kinase, creatine kinase-MB, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine, blood urea nitrogen, serum sodium, serum potassium, serum chloride, and serum magnesium. The minimum value in the first 24 h in the ICU was selected for the following variables: hemoglobin, platelet, and albumin

Table 3

Severity of illness scores, treatments and outcomes of included patients

Variables	All, n = 944	Non-thiamine, n = 711	Thiamine, n = 233	P value
Scores
GCS	15 (13–15)	15 (13–15)	14 (12.5–15)	0.001
MELD	16 (9–25)	16 (9–25)	14 (8–22)	0.023
SOFA	5 (4–8)	6 (4–8)	5 (3–7)	0.164
OASIS	34 (28–40)	34 (28–40)	36 (30–41)	0.003
LODS	5 (3–7)	5 (3–7)	5 (3–7)	0.582
Interventions on day 1, n (%)
Mechanical ventilation	553 (58.6)	408 (57.4)	145 (62.2)	0.192
Vasopressor	323 (34.2)	247 (34.7)	76 (32.6)	0.554
CRRT	39 (4.1)	30 (4.2)	9 (3.9)	0.812
Primary outcome
28-day mortality, n (%)	158 (16.7)	132 (18.6)	26 (11.2)	0.009
Secondary outcome
ICU mortality, n (%)	106 (11.2)	91 (12.8)	15 (6.4)	0.008
In-hospital mortality, n (%)	147 (15.6)	124 (17.4)	23 (9.9)	0.006
90-day mortality, n (%)	200 (21.1)	164 (23.1)	36 (15.5)	0.014
ICU length of stay, day	3.7 (1.9–8.5)	3.2 (1.8–7.4)	5.0 (2.2–9.8)	< 0.001
Hospital length of stay, day	10.0 (5.5–17.6)	9.4 (5.2–17.0)	11.8 (6.4–18.1)	0.003
Duration of vasopressor use during ICU stay, hours	46 (15–113)	41 (15–108)	58 (12–121)	0.456
Duration of CRRT use during ICU stay, h	78 (36–115)	73 (34–108)	96 (47–135)	0.549

For the severity of illness scores, we selected the maximum value in the first 24 h in the ICU for the following variables: MELD, SOFA, OASIS, LODS. We selected the minimum value of GCS in the first 24 h in the ICU

GCS Glasgow Coma Scale, MELD Model for End-stage Liver Disease, SOFA Sequential Organ Failure Assessment, OASIS Oxford Acute Severity of Illness Score, LODS Logistic Organ Dysfunction Score, CRRT continuous renal replacement therapy, ICU intensive care unit

Interventions

Of the 233 patients who received continuous intravenous administration of thiamine, 75.1% (175/223) and 92.3% (215/233) of patients received first thiamine treatment within 24 h and 72 h after ICU admission, respectively. Most patients (179/233, 76.8%) received a dose of 100 mg once daily, and only 12 patients (5.2%) received more than 200 mg. The median cumulative dose of thiamine used during ICU stay was 200 mg (IQR 100–345 mg). Approximately half of the patients (125/233, 53.6%) received thiamine administration in ICU for  1 day, and only 7.7% of patients (18/233) received thiamine on 5 days or more. The median duration of thiamine use in ICU was 1 day (IQR 1–3), and the cumulative median duration of thiamine treatment was 18 h (IQR 7–63 h) (Supplementary Table S2).

Primary Outcome

The primary outcome, 28-day mortality, was significantly lower in the thiamine group compared with the no thiamine group (11.2% vs. 18.6%, P = 0.009) (Table 3). Figure 2 shows the cumulative mortality (log-rank test P = 0.007). After adjustment for a series of confounders, such as age, gender, admission type, primary infection site, heart rate, blood pressure, international normalized ratio, total bilirubin, serum creatinine, blood urea nitrogen, serum potassium, GCS, MELD, and OASIS, the mixed-effects Cox proportional hazards models showed that administration of thiamine was associated with a lower risk of 28-day mortality compared with non-thiamine [all adjusted hazard ratio (HR) < 1 and P < 0.05] (Table 4).

Fig. 2

Cumulative incidence of the primary outcome of 28-day survival for thiamine use vs. no thiamine use

Table 4

Hazard ratios and 95% CIs for 28-day all-cause mortality associated with the thiamine use in patients with sepsis and alcohol use disorder

Regression models	Multivariable
	HR (95% CI)	P value
Unadjusted	0.566 (0.372–0.862)	0.008
Model 1	0.633 (0.414–0.970)	0.036
Model 2	0.643 (0.418–0.988)	0.044
Model 3	0.610 (0.385–0.967)	0.035
Model 4	0.594 (0.375–0.941)	0.026
Model 5	0.626 (0.407–0.963)	0.033
Model 6	0.561 (0.365–0.863)	0.008

Model 1 was adjusted for age, gender, admission type, and primary infection site. Model 2 was adjusted for the confounders included in model 1 plus vital signs (heart rate and blood pressure). Model 3 was adjusted for the confounders included in model 2 plus laboratory tests (international normalized ratio, total bilirubin, serum creatinine, blood urea nitrogen, and serum potassium). Model 4 was adjusted for the confounders included in model 3 plus GCS. Model 5 was adjusted for the confounders included in model 2 plus GCS and MELD. Model 6 was adjusted for the confounders included in model 2 plus OASIS

GCS Glasgow Coma Scale, MELD Model for End-stage Liver Disease, SOFA Sequential Organ Failure Assessment, OASIS Oxford Acute Severity of Illness Score, ICU intensive care unit

Secondary Outcomes

Table 3 shows the secondary outcomes between the two groups. The ICU, in-hospital, and 90-day mortality rates in the treatment group were significantly lower than those in the control arm (6.4% vs. 12.8%, P = 0.008; 9.9% vs. 17.4%, P = 0.006; 15.5% vs. 23.1%, P = 0.014; respectively). The ICU and hospital stay duration for patients with thiamine use were significantly longer than for the no thiamine group (5.0 days vs. 3.2 days, P < 0.001; 11.8 days vs. 9.4 days, P = 0.003; respectively). There were also no differences in the duration of vasopressor use or CRRT use among the two groups (Table 3 and Supplementary Table S3). The trends for heart rate, respiratory rate, systolic blood pressure, diastolic blood pressure, lactate, white blood cell count, alanine aminotransferase, aspartate aminotransferase, serum creatinine, blood urea nitrogen, serum magnesium, GCS, and MELD up to day 7 were similar between the two groups (Fig. 3, Supplementary Fig. S2 and Table S4).

Fig. 3

Dynamic changes for prespecified variables: a heart rate, b systolic blood pressure, c lactate, d serum creatinine, e Glasgow Coma Scale, f MELD. MELD Model for End-stage Liver Disease. The square icon in each group represented the mean value. *P < 0.05

Subgroup Analyses

There were statistically significant interactions for three subgroups: (1) those with lower vs. higher lactate levels (HR 0.631 [0.238–1.674] vs. 0.454 [0.259–0.796], P = 0.009 for interaction), (2) those without vs. with the need for mechanical ventilation on ICU day 1 (HR 0.940 [0.509–1.744] vs. 0.393 [0.219–0.705], P = 0.009 for interaction), and (3) those with higher vs. those lower OASIS (HR 0.718 [0.318–1.620] vs. 0.467 [0.285–0.763], P = 0.040 for interaction) (Fig. 4).

Fig. 4

Subgroup analysis for primary outcome defined by population. SOFA Sequential Organ Failure Assessment, OASIS Oxford Acute Severity of Illness Score, HR hazard ratio

Among patients with thiamine therapy, all-cause 28-day mortality was numerically lower in the cumulative dose of 100 to 200 mg (4.5%) vs. other dose groups (11.8% for cumulative dose with < 100 mg, 10.5% for a cumulative dose of 200–345 mg, 15.5% for cumulative dose > 345 mg), but it did not achieve statistical significance (P = 0.375) (Supplementary Fig. S3). Furthermore, after adjustment for potential confounders, no differences were found in 28-day mortality between patients with different doses of thiamine during ICU stay (Fig. 5). A similar result indicated insignificant association between time of thiamine use and 28-day mortality in patients with sepsis and AUD (P = 0.451) (Supplementary Fig. S4).

Fig. 5

Restricted cubic spline and kernel density plot of the association between cumulative dose of thiamine administered during ICU stay and 28-day mortality. Results were adjusted for age, gender, admission type, primary infection site, and baseline SOFA score. The models were expressed relative to the median doses, and the dotted lines represent the 95% confidence intervals for the spline model (reference is 200 mg). The area shown in purple is the kernel density plot, which demonstrates the distribution of the cumulative dose of thiamine administered. SOFA Sequential Organ Failure Assessment, ICU intensive care unit

Discussion

To our knowledge, this is the most extensive descriptive study for the association between thiamine administration and the outcomes of patients with sepsis and AUDs. In this study, we found that receiving thiamine was associated with a lower risk of 28-day mortality than no thiamine administration in patients with sepsis and AUDs, especially in patients with higher lactate levels and greater severity of illness and need for mechanical ventilation on ICU day 1.

AUD is often combined with thiamine deficiency that results in some severe complications [18]. The most common and severe complication is Wernicke’s encephalopathy (WE), with a frequency of about 35% in chronic alcoholics [19]. Furthermore, some studies have shown that alcohol dependence is independently associated with sepsis and increased incidence of multiple organ dysfunction and sepsis-related hospital mortality [20, 21]. Sepsis is also associated with thiamine deficiency [22]. Thus, it is likely that thiamine supplementation may provide some benefits to patients with sepsis and AUD. Some previous randomized controlled trials (RCTs) have emphasized the effect of thiamine in sepsis; however, the results are mostly negative [6, 23–25]. The reason is that these studies only focus on the thiamine administration in patients with sepsis, not in patients with sepsis and AUD; on the other hand, these RCTs had a relatively small sample size, which would reduce the confidence of the outcome. A small retrospective cohort study (N = 53) reported that thiamine administration in patients with AUD admitted for septic shock was associated with decreased mortality (thiamine group 44% vs. no thiamine group 79%, P = 0.02) [9]. The result of our study was aligned with this previous research, indicating that administration of thiamine was independently associated with a lower risk of 28-day mortality compared with patients not administered thiamine during sepsis among individuals with AUD. We reported that the mortality differences lasted up to the 90-day follow-up (15.5% vs. 23.1%, P = 0.014).

Despite the potential benefits of thiamine administration, its low side-effect profile, and cost, the percentage of patients who received thiamine was only 24.7% in patients with sepsis and AUD. This is in accordance with Pawar et al.’s recent study [26]. In a nationwide retrospective observational study, the thiamine supplementation was seen in 59% of patients with AUD but the rate was significantly decreased in patients with sepsis and AUD [26]. This obvious difference gap may be associated with care provider’s variability. Among patients with AUD admitted for sepsis, care providers may be more focused on sepsis compared with AUD. This may explain the lower-than-expected rate of thiamine supplementation in patients with sepsis and AUD. Treatment with thiamine in patients with AUD is recommended in the USA [27] and Europe [28]. However, the administration details, including timing, dosing, and route of administration, are still unclear. We noted that 75.1% and 92.3% of patients received first thiamine via intravenous routes within 24 h and 72 h after ICU admission, respectively. However, we did not find any significant difference in 28-day mortality between patients with different doses of thiamine during ICU stay. Further research is needed to evaluate the doses of thiamine for mortality in patients with sepsis and AUD.

Thiamine is an essential cofactor for pyruvate dehydrogenase (PDH), the initial enzyme for Krebs cycle [29]. Severe thiamine deficiency can result in lower PDH function, and it could, in turn, lead to lower pyruvate conversion to acetyl coenzyme A. This phenomenon indirectly promotes the conversion of pyruvate to lactic acid, resulting in mitochondrial aerobic metabolism disturbances and multiple organ dysfunction [30]. Having said that, the exact mechanism of improved survival by thiamine supplementation in this cohort is still unclear. We did not find differences in cardiovascular (systolic blood pressure and need for vasopressors), kidney (serum creatinine and need for CRRT), and liver (MELD score) functions. Despite the statistical differences in daily trends for GCS, slight changes in consciousness did not significantly increase mortality (Supplementary Table S5). These findings may mean that the observed survival benefits of thiamine administration could be independent of organ dysfunction. Although there were no statistically significant differences in lactate levels between the two groups, there was a tendency to lower lactate among those who received thiamine. Notably, in subgroup analysis, higher lactate level (≥ 2 mmol/L) and higher SOFA score (≥ 5) were associated with lower mortality when patients received thiamine. Therefore, it is likely that choosing appropriate target patients for thiamine therapy could lead to higher benefits. Receiving thiamine may reduce the gap between macro- and microcirculation, promote the aerobic metabolism in mitochondria, and restore the impaired tissue perfusion leading to improved patient outcomes. Donnino and colleagues found that thiamine administration in patients with septic shock and baseline thiamine deficiency could significantly decrease the lactate level at 24 h and possibly reduce mortality [25].

Our study has several limitations. First, the wide existence of immortal time bias in observational studies may exaggerate the association between thiamine and survival among patients with sepsis and AUD. We have attempted to partly mitigate this effect by utilizing the Cox model. Second, as a result of its retrospective design, we are not able to imply any causal relationship. Hence, prospective studies are required to verify the results of our hypothesis-generating study. Third, we cannot identify thiamine deficiency because of the lack of baseline thiamine levels in MIMIC-III. Therefore, we cannot infer whether all patients with sepsis and AUD can benefit or only the thiamine-deficient individuals. Fourth, in the thiamine group, 53.6% of patients received thiamine for only 1 day, and 4.3% of patients received thiamine with a cumulative dose of less than 100 mg. The lower thiamine doses used in these individuals make it difficult to assess the dose-dependency of thiamine effects; the heterogeneous doses and time of thiamine administration could limit the application of these results. Fifth, thiamine supplementation should be routinely recommended in today’s management of AUD; however, as only 24.7% of patients received thiamine supplementation in our study, this may be related to the time period of MIMIC-III. Lastly, the adjustments in our study may not sufficiently address all confounding variables, and some confounders may have remained unaccounted for, such as care provider variability. Owing to the aforementioned limitations, although there is a significant difference in mortality, the present results should be interpreted with caution.

Conclusions

In critically ill patients with alcohol use disorder admitted for sepsis, treatment with thiamine may be associated with a decreased risk of death. However, the present results should be interpreted with caution because of the limitations of retrospective design. Additional larger, multicenter randomized controlled trials are needed to confirm our findings.

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 1099 KB)

Why carry out this study?

Sepsis is a common condition that is associated with unacceptably high mortality. Patients with sepsis and alcohol use disorder (AUD) are frequently thiamine deficient due to malnutrition or malabsorption.

Clinical outcomes of thiamine use in patients with sepsis and AUD have not been investigated.

We aimed to investigate the association between thiamine administration and the 28-day mortality among patients with sepsis and AUD in a large cohort of patients.

What was learned from the study?

In critically ill patients with AUD admitted for sepsis, treatment with thiamine may be associated with a decreased risk of death. Additional larger, multicenter trials are needed to confirm our findings.

Patients with AUD admitted for sepsis with higher lactate levels and greater severity of illness and need for mechanical ventilation on ICU day 1 may benefit from administration of thiamine.